‘Smart’ Nanoparticles Deliver mRNA Directly to Tumors in New Cancer Therapy
Researchers have developed 'smart' nanoparticles designed to deliver mRNA therapy directly to tumor-associated macrophages. By targeting these specific cells, the treatment aims to reprogram the tumor environment to allow T cells to effectively attack cancer cells while minimizing systemic immune side effects.
Why it matters
This targeted delivery method could significantly improve the efficacy and safety of cancer immunotherapies by overcoming the immunosuppressive barriers created by tumors.
Overcoming the oppressive tumor environment remains a barrier for even some of the most promising treatments. “One of the biggest challenges in cancer immunotherapy is that the immune system may be capable of attacking a tumor, but the tumor environment can stop those immune cells from doing their job,” University of Adelaide professor Chunxia Zhao explained in a press release.
In a study published this week in Science Advances, Zhao’s team developed a system that can precisely deliver an mRNA therapy to transform immune cells back into allies. The researchers focused on tumor-associated macrophages, which—when rewired by signals from the cancer—hinder the arrival and activity of T cells, one of the body’s main weapons against cancer. The mRNA carries the instructions for producing CXCL9, a chemical signal for recruiting T cells.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in